Full-Time
Team Leader / French Native Speaker
Confirmed live in the last 24 hours
IQVIA
10,001+ employees
Provides analytics and clinical research services
No salary listed
Mid, Senior
Company Historically Provides H1B Sponsorship
Madrid, Spain
- High school graduate or equivalent.
- Native or bilingual level of French is required (interviews will be conducted in this language)
- Very high level of English is required.
- Experience working for multi-national corporations is an advantage.
- Experience in team management.
- Good skills with Microsoft Excel is needed.
- Highly organized with experience in working accurately with tight deadlines and under pressure.
- Must have strong prioritization skills and the ability to work in a multitask environment.
- Coordinate activities, resources, equipment and information.
- Plan, coordinate and follow-up fieldwork stages for PI projects.
- Implement and follow procedures to monitor and control data collection flow, ensuring regular reports on project evolution and that FW and data delivery timelines are met.
- Monitor key project metrics to drive internal and external client satisfaction.
- Effectively work and communicate with a multi-cultural and cross-functional team.
- Apply critical thinking skills in order to foresee any potential difficulties and find solutions to avoid them.
- Develop FW knowledge by identifying market insights in order to provide support on project definition: sample estimation, scope, objectives, timeframes and budget.
- Lead and guide the interviewer team during the project lifespan.
- Analyse Panel Sample design to ensure feasibility and Follow-up of Design Fulfilment.
- Recruit target doctors and follow-up on their participation. Create doctor’s engagement.
- Promotes HCP collaboration in syndicated, ad-hoc PMR studies based on established standards. Initiates follow-up calls with panellists to achieve maximum rate of return.
- Transition doctors to the official Incentive Program and support implementation of adaption to Local Fiscal / Legal regulations. Investigates, resolves and processes panel incentives issues within defined guidelines in order to facilitate timely receipt of compensation.
- Support doctor during their E to E participation and act as the Voice of Doctor in new projects, set-ups, market analysis feasibility, etc.
- Work cross-functionally with coding team to resolve data quality issues.
- Experience working for multi-national corporations is an advantage.
- Experience in team management.
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes big data and technology to offer insights that help clients speed up the development and marketing of new medical treatments. This system connects various healthcare data points to provide a comprehensive view of patient needs and treatment effectiveness. Unlike many competitors, IQVIA places a strong emphasis on patient privacy, using advanced technologies to protect individual data. The company's goal is to enhance healthcare outcomes by supporting biotech, pharmaceutical, and medical device companies, as well as researchers and government agencies, in their efforts to understand diseases and improve treatment options.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- Med-R1 8B offers a competitive edge in AI-driven healthcare solutions.
- Site Lab Navigator improves efficiency in clinical trial processes.
- IQVIA's leadership in decentralized trials highlights growth potential.
What critics are saying
- Emerging competition from preventive wellness companies like Vimergy.
- Disparities in CAR T-cell therapy access may lead to reputational risks.
- Increased scrutiny on AI ethics and patient data privacy.
What makes IQVIA unique
- IQVIA's Med-R1 8B model outperforms larger models in medical reasoning.
- Site Lab Navigator's e-Requisition innovation streamlines clinical trial processes.
- IQVIA is recognized as a leader in decentralized clinical trial technologies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication
NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments.
IQVIA has launched Med-R1 8B, a medical reasoning large language model (LLM) designed to assist healthcare professionals in interpreting complex clinical data and scientific literature.
COLLEGE PARK, Md., March 26, 2025 /PRNewswire/ -- Registration is open for "Business of Life Sciences and Healthcare for Leaders" (B-LSHC) — an immersive five-day program focused on leadership development and honing critical-thinking and problem-solving skills in medical product development presented by Smith Executive Education at the University of Maryland's Robert H. Smith School of Business.The in-person program takes place June 23-27, 2025, at Van Munching Hall on UMD's College Park campus and is designed for mid-to-advanced career professionals in the LSHC ecosystem including pharmaceutical, biotech and medical device industries; health policy; patient advocacy; regulators; investors; and leaders across medical and regulatory fields.Program sessions will begin at 8:30 a.m. each day "and end with a luminary keynote speaker who will inspire and challenge participants to think outside the box toward the goals of creating innovative solutions for some of our most challenging problems in the LSHC ecosystem," says Wendy Sanhai, PhD, professor of the practice in management and organization for the Smith School and one of the workshop's organizers.Participants will learn from world-renowned faculty, regulatory experts and industry leaders on how to make informed decisions at crucial stages of medical product (drugs, biologics and medical devices) development – from R&D and regulatory submission to commercial launch and reimbursement. And, through expert-led sessions, dynamic capstone project discussions and case-study analysis, participants will sharpen their problem-solving and critical-thinking skills as they expand their professional network.Instructors, in addition to Sanhai, will include UMD and Smith faculty experts Balaji Padmanabhan, director of Smith's Center for Artificial Intelligence in Business; management and organization professors Jennifer Carson Marr, Oliver Schlake and Subra Tangirala; marketing professor Judy Frels; School of Public Health Dean Boris Lushniak; and School of Pharmacy Professor Joga Gobburu.The UMD experts will be joined by leading industry experts including former CEO of Scorpion Therapeutics Axel Hoos, IntoValue CEO Marion Couch, Deloitte Principals Juergen Klenk, Candy Lurken and Mathias Cousin; Euclidean Life Science Advisors President Kenneth Moch; Licensing IP negotiator Steve Ferguson; leaders from IQVIA and former FDA leaders.Participants will:Sharpen problem-solving, leadership and critical-thinking skillsCultivate holistic thinking and multidisciplinary approaches for real-world problems in the LSHC ecosystemBuild upon lessons learned and best practices from regulatory experts, industry luminaries and academic leadersExpand their professional networkIdentify major milestones, potential challenges, risks and mitigation strategies across medical product development pathways in R&D, regulatory submission, product launch and commercializationExecute critical steps in license negotiations and technology transfer processesParticipants should have at least a bachelor's degree and five years of working experience in any LSHC field.Scholarships are available, including for nonprofits, government professionals and veterans. Discounts are available for organizations with multiple participants. Information sessions via Zoom are set for 1-2 p.m